This report offers a summary of the provided support and recommendations on priority activities for IPC improvement at national and facility levels. The COVID-19 pandemic spotlighted areas for improvement in the IPC programme at national and facility levels. Improvements in the IPC programme were ac...hieved during the acute phase of the pandemic response. WHO will continue to support the Ministry Health of Ukraine and the Public Health Centre, as well as health facility managers and health-care providers, on the next steps to ensure the sustainability of progress achieved and to further enhance IPC in health-care settings.
more
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more
A Situational Assessment and Five-YearAction Plan for the Africa CDC Strengthening Regional Public Health Institutions and Capacity for Surveillance and Response Program
The NY Times variant tracker is perhaps the most accessible and relevant publication for non-molecular biologists and the general public
Each coronavirus contains nearly 30,000 letters of RNA. This genetic information allows the virus to infect cells and hijack them to make new viruses.
These Blended Learning Modules have been produced in collaboration with the Ethiopian Federal Ministry of Health (FMOH) and Regional Health Bureaus (RHBs) as well as a range of medical experts and health science specialists within Ethiopia. They are being used to upgrade the theoretical knowledge of... the country's 33,000 rural Health Extension Workers to that of Health Extension Practitioners and to train new entrants to the service.
The Modules are Open Educational Resources (OERs) and are free for everyone to use. You can download them as they are or adapt them to fit your specific context. The OERs cover the full range of health promotion, disease prevention, basic management and essential treatment protocols to improve and protect the health of rural communities.
more
If you have been wondering when you would receive your vaccine? Why you should get vaccinated and are concerned about what your are hearing about side effects, this episode of Science with 5 with WHO’s Chief Scientist Dr Soumya Swaminathan is for you.
This Rapid Communication aims to inform national TB programmes and other stakeholders about the key implications of the latest evidence on the use of specific molecular assays as initial diagnostic tests of pulmonary and extrapulmonary TB and RR-TB, in adults and children.
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Ra...pid Communication is released in advance of updated WHO consolidated guidelines expected later in 2022, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.
more